ER-to-Golgi transport of coagulation factors V and VIII

凝血因子 V 和 VIII 的内质网至高尔基体转运

基本信息

  • 批准号:
    7837197
  • 负责人:
  • 金额:
    $ 18.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

Description (provided by the applicant): Coagulation factors V (FV) and factor VIII (FVIII) are both secreted glycoproteins that share pivotal roles in both hemostasis and thrombosis. Although many secreted proteins (referred to as cargo) are believed to require transport receptors for efficient ER-to-Golgi transport, only a limited number of such receptors have been described, mostly in yeast. Evidence for the existence of mammalian cargo receptors came unexpectedly from studies of the human genetic disorder combined deficiency of FV and FVIII, which identified mutations in LMAN1 and MCFD2 as the cause of the disorder. Combined deficiency of FV and FVIII is a rare bleeding disorder characterized by coordinate reduction of both FV and FVIII to the range of 5-30% of normal. LMAN1 and MCFD2 form a Ca2+-dependent protein complex in the ER-Golgi intermediate compartment that interacts with FV and FVIII, suggesting that the LMAN1-MCFD2 complex is a cargo receptor required for efficient transport of FV and FVIII from the ER to the Golgi. Mice deficient in LMAN1 model the human disorder but also exhibit a strain-specific perinatal lethality that is not explained by the reduced FV/FVIII levels, indicating additional functions of LMAN1. Using LMAN1 and MCFD2 deficient mice, proposed research will elucidate structure-function relationship of the LMAN1-MCFD2 receptor complex, and its requirement for the secretion of FV and FVIII and other potential cargo proteins in vivo. Proposed studies will not only answer fundamental questions regarding the mechanism of LMAN1-MCFD2 receptor-mediated secretion of FV and FVIII, but will also provide fundamental new insights into general mechanism of mammalian ER-to-Golgi protein transport. Genetic deficiency of FVIII results in hemophilia A, which affects ~1 in 5000 males. On the other hand, a gain-of-function mutation in FV (FV Leiden) and increased FVIII activity are major risk factors for venous thrombosis, which affects ~1:1,000 individuals in the US per year. The findings will have practical importance for improving FVIII expression and may expedite the eventual goal of somatic cell gene therapy for hemophilia A, as well as new approaches to limiting FV and FVIII production in prothrombotic states. PUBLIC HEALTH RELEVANCE: The project will study a transport receptor that when absent, cause a human genetic disorder with low levels of blood coagulation factors V and VIII. The goal is to understand how this transport receptor controls two different blood coagulation factors and hopefully use the knowledge to benefit people with hemophilia A and venous thrombosis.
描述(由申请人提供):凝血因子V (FV)和凝血因子VIII (FVIII)都是分泌的糖蛋白,在止血和血栓形成中都起着关键作用。尽管许多分泌蛋白(称为货物)被认为需要转运受体来进行高效的ER-to-Golgi转运,但只有有限数量的此类受体被描述,主要是在酵母中。哺乳动物货物受体存在的证据出乎意料地来自人类遗传疾病FV和FVIII联合缺乏的研究,该研究确定LMAN1和MCFD2突变是该疾病的原因。FV和FVIII合并缺乏症是一种罕见的出血性疾病,其特征是FV和FVIII同时降低至正常值的5-30%。LMAN1和MCFD2在ER-高尔基体中间区形成Ca2+依赖性蛋白复合物,与FV和FVIII相互作用,表明LMAN1-MCFD2复合物是FV和FVIII从内质网有效运输到高尔基体所需的货物受体。缺乏LMAN1的小鼠模拟了人类疾病,但也表现出菌株特异性的围产期死亡率,这不能用FV/FVIII水平降低来解释,这表明LMAN1具有其他功能。利用LMAN1和MCFD2缺陷小鼠,拟开展的研究将阐明LMAN1-MCFD2受体复合物的结构-功能关系,以及其在体内分泌FV和FVIII等潜在货物蛋白的需求。拟议的研究不仅将回答关于LMAN1-MCFD2受体介导的FV和FVIII分泌机制的基本问题,而且将为哺乳动物ER-to-Golgi蛋白运输的一般机制提供新的基础见解。FVIII基因缺陷导致A型血友病,在5000名男性中约有1人患病。另一方面,FV的功能获得性突变(FV Leiden)和FVIII活性增加是静脉血栓形成的主要危险因素,在美国每年约有1:10 000人受其影响。这一发现对于改善FVIII表达具有重要的实际意义,并可能加快血友病A体细胞基因治疗的最终目标,以及限制血栓前状态FV和FVIII产生的新方法。公共卫生相关性:该项目将研究一种运输受体,当缺乏这种受体时,会导致血液凝固因子V和VIII水平低的人类遗传疾病。我们的目标是了解这种转运受体如何控制两种不同的凝血因子,并希望利用这些知识来造福A型血友病和静脉血栓患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bin Zhang其他文献

Bin Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bin Zhang', 18)}}的其他基金

The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells
半胱氨酰白三烯受体对骨髓源性抑制细胞的独特作用
  • 批准号:
    10398916
  • 财政年份:
    2020
  • 资助金额:
    $ 18.85万
  • 项目类别:
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells
半胱氨酰白三烯受体对骨髓源性抑制细胞的独特作用
  • 批准号:
    10162565
  • 财政年份:
    2020
  • 资助金额:
    $ 18.85万
  • 项目类别:
From epigenome to genome and back: disentangling the relationship between epigenetic modifications and chromatin organization
从表观基因组到基因组并返回:理清表观遗传修饰与染色质组织之间的关系
  • 批准号:
    10178047
  • 财政年份:
    2019
  • 资助金额:
    $ 18.85万
  • 项目类别:
From epigenome to genome and back: disentangling the relationship between epigenetic modifications and chromatin organization
从表观基因组到基因组并返回:理清表观遗传修饰与染色质组织之间的关系
  • 批准号:
    10437740
  • 财政年份:
    2019
  • 资助金额:
    $ 18.85万
  • 项目类别:
From epigenome to genome and back: disentangling the relationship between epigenetic modifications and chromatin organization
从表观基因组到基因组并返回:理清表观遗传修饰与染色质组织之间的关系
  • 批准号:
    10618347
  • 财政年份:
    2019
  • 资助金额:
    $ 18.85万
  • 项目类别:
WEE1 inhibition and tumor immunity
WEE1抑制和肿瘤免疫
  • 批准号:
    10241248
  • 财政年份:
    2018
  • 资助金额:
    $ 18.85万
  • 项目类别:
WEE1 inhibition and tumor immunity
WEE1抑制和肿瘤免疫
  • 批准号:
    10440520
  • 财政年份:
    2018
  • 资助金额:
    $ 18.85万
  • 项目类别:
The role of GPSM3 in tumor-promoting emergency myelopoiesis
GPSM3在促肿瘤紧急骨髓细胞生成中的作用
  • 批准号:
    10115623
  • 财政年份:
    2017
  • 资助金额:
    $ 18.85万
  • 项目类别:
The role of GPSM3 in tumor-promoting emergency myelopoiesis
GPSM3在促肿瘤紧急骨髓细胞生成中的作用
  • 批准号:
    9449420
  • 财政年份:
    2017
  • 资助金额:
    $ 18.85万
  • 项目类别:
CD73 and Tumor Immunity-CD73 and CTLA-4 combination Blockade in Ovarian Cancer
CD73 和肿瘤免疫——CD73 和 CTLA-4 联合阻断卵巢癌
  • 批准号:
    8628468
  • 财政年份:
    2011
  • 资助金额:
    $ 18.85万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.85万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了